Chief Financial Officer · Rani Therapeutics Holdings, Inc. (RANI)

Svai Sanford

A named executive officer of Rani Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$946,404

Salary $392,711Stock awards $0Bonus $139,000

FY2024: $1,291,456

2nd of 3 named executive officers at Rani Therapeutics by FY2025 total.

3 named officers on file for Rani Therapeutics, FY2025

Svai Sanford’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Rani Therapeutics’s whole pay program stands against its peers

  • Rani Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RANI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2026 (DEF 14A).

Free

Get Svai Sanford’s full pay file as a PDF — free

More than this page: up to 10 years of Svai’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Svai Sanford compensation by year

Rani Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Rani Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$416,000$392,711
Bonus$0$139,000
Stock awards$0$0
Option awards$875,456$154,993
Non-equity incentive$0$259,700
Pension and deferred compensation$0$0
All other$0$0
Total$1,291,456$946,404

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Rani Therapeutics Holdings, Inc. DEF 14A filed April 16, 2026, accession 0001140361-26-015157, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Rani Therapeutics Holdings, Inc. filed document, accession 0001140361-26-015157. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.

$1.3M
$946K
FY24
FY25
SalaryBonusNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU43,438$58,641—
RSU8,225$11,104—
Option277,605—$0.62
Option181,969—$3.60
Option64,313—$2.84
Option6,250—$2.84

Per the Outstanding Equity Awards at Fiscal Year-End table in Rani Therapeutics Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Rani Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Talat ImranChief Executive Officer$1,052,101
Svai Sanford · this pageChief Financial Officer$946,404
Kate McKinleyChief Business Officer$943,937

The full Rani Therapeutics compensation record

free company brief

This page is one person within Rani Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Rani Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Svai Sanford's compensation dossier · One-time report. No refunds.